CHANGING THE WAY THE WORLD BREATHES

RHINOMED - NASAL RESPIRATORY TECHNOLOGY

MASTER INVESTOR APRIL 2016
Disclaimer

This document contains certain forward-looking statements, relating to Rhinomed Limited’s (Rhinomed) business which can be identified by the use of forward looking terminology such as “promising”, “plans”, “anticipated” “will,” “project,” “believe,” “forecast”, “expected,” “estimated”, “targeting,” “aiming”, “set to”, “potential,” “seeking to”, “goal”, “could provide,” “intends”, “is being developed”, “could be,” “on track” or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company’s technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects.

Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward looking statements contained in this document as a result of new information, future events or developments or otherwise.
Pursuing a Significant Global Opportunity

Rhinomed is amplifying the belief that better breathing can radically improve how you perform, recover, sleep and maintain your health by creating the world’s most elegant, innovative and clinically backed nasal respiratory technology.

We partner with the world’s best and brightest people to make this a reality.
WHO IS RHINOMED?

<table>
<thead>
<tr>
<th><strong>ASX: RNO</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early stage medical technology company</td>
<td>Cash on Hand ~ 4.0 Million</td>
</tr>
<tr>
<td>Offices: Melbourne, Australia and Cincinnati, USA</td>
<td>Revenues FY YTD – AU$750k</td>
</tr>
<tr>
<td>Share Price ~AU$0.024</td>
<td>Staff 11</td>
</tr>
<tr>
<td>Market Cap ~ AU$ 17 million</td>
<td>60+ patents, 13 granted plus additional 57 design patents</td>
</tr>
</tbody>
</table>

Globally experienced board and management team

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr Ron Dewhurst - Chairman</td>
<td>Mr Michael Johnson – CEO and Managing Director</td>
</tr>
<tr>
<td>Mr Brent Scrimshaw - Non Exec Director</td>
<td>Ms Justine heath - CFO</td>
</tr>
<tr>
<td>Dr Eric Knight - Non Exec Director</td>
<td>Mr Shane Duncan – Head Americas</td>
</tr>
</tbody>
</table>
# A Novel Nasal Technology Platform

<table>
<thead>
<tr>
<th>Product</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Regulatory</th>
<th>In Market</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TURBINE 2.0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC Dyspnea in</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sport and Exercise</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MUTE 1.0</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC Snoring and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep Quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Congestion - OTC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hayfever - OTC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anxiety - OTC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sleep Apnea</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drug Delivery – Acute Migraine</strong> (sumatriptan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- FDA
- TGA
- CANADA HEALTH
- CE Mark

- Seeking to partner
TURBINE – SPORT BREATHING TECHNOLOGY

• TURBINE 2.0 - Released Feb 2015
• Designed to help athletes breathe easier during sport and aerobic exercise and helps those suffering from nasal obstruction
• Now distributed globally
• Available in three sizes and a trial pack
• RRP US$27.95 delivering strong margins
Turbine helped Chris Froome win his second Tour de France
Turbine helped Shannon Rowbury set a new American record for the 1500 meters.
**SLEEP IS A MAJOR EMERGING MARKET**

Apple included a new ‘blue light function in their new iphone OS release in March ‘16

Huffington Post founder Arianna Huffington is taking the US by storm

Sleep is being picked up mainstream media as a ‘health story’
MUTE - CATEGORY DEFINING BRANDED TECHNOLOGY

- Mute released January 2015
- Front line therapy – Snoring and sleep quality
- Available in three sizes and a trial pack
- RRP £$16.99 – delivering strong margins
- 1 pack = 1 months supply (10 uses per individual unit)
Mute Works – User Product Trial Results

75%

Of the subjects reported a reduction in the incidence & severity of snoring

2014 User Trial. N=236 includes 5 days of continual use.

78% Improvement in breathing at night
73% Reduction in snoring severity
65% Reduction in snoring duration
67% Reduction in snoring volume
63% Reduction in snoring frequency

Mute User trial. N=236. 5 Day in-home user trial. November 2014

© RHINOMED LTD 2015
WWW.RHINOMED.GLOBAL
RHINOMED HAS A UNIQUE, CUT THROUGH BRAND
CUSTOMERS LOVE MUTE

The wife who's Britain's loudest snorer: Retired bank worker is as noisy as a low-flying jet and her husband hasn't had a decent night's sleep for 30 years

Jenny Chapman's strange claim to fame is she's the UK's loudest snorer. Six years ago Jenny enlisted herself in a boot camp for chronic snorers. Her snoring was recorded at a remarkable 111 decibels, the same as a jet. Colin has shared his wife's bed for 30 years, and is woken up every night.

By JENNY JOHNSTON FOR THE DAILY MAIL

Jenny Chapman, who has the allegedly embarrassing accolade of being Britain's loudest snorer.

Just as Eskimos have 50 words for snow, so Colin Chapman thinks we should have an entire range of expressions for 'snore'... 'It's so vague, isn't it?' he asks. 'People say to me: Oh my partner snores... But that can mean anything. Snoring can be a bit of a marinating in your sleep. It can also be making the sort of noise that takes the roof off. There really should be a special word for the type that wakes me up at 2am today. It was like a bumerang flying at you.'

It seems we know at least 50 different types of snore...

When he says 'yes', he means him and his wife, Jenny, who has an unusual claim to fame - one she's a little embarrassed about, and one Colin isn't quite sure whether to be proud of or not.

For Jenny Chapman is officially Britain's loudest snorer. How does one get such an accolade? Well, six years ago, after decades of disrupted sleep and banishment to the spare room, Jenny, a retired bank worker, sought help and enlisted herself in a boot camp for chronic snorers.

Her snoring levels were recorded and the decibels measured. Further examination - but not bloody mince - spirited out Colin, who sounds a touch like Gyles' Len Goodman, and has the patience to match - her snoring was as loud as a low-flying jet, soaring in at a remarkable 111 decibels.

Colin, who has shared his wife's bed for more than 30 years, is still talking about the fact that such ear-piercing levels were recorded and made official.

"I was undated," he says. "All those years I'd spent saying to her 'Blimey, Jenny, you sounded like a fighter jet' - and I was proved right."

Professor Narayana, the partner under a flight path in Prestwick and Colin is something of an aeroplane buff. He can only say that his wife's snoring resembles a jet, but can pinpoint exactly what sort of jet it resembles.

"You know when a fighter suddenly pulls up, when the engines are on their feet and you get that roar, followed by a sizzle?" Er, no. Well, that's exactly what Jenny sounds like, when I hear it happening for me, I dash outdoors to look up at the sky. In the middle of the night, I just sit up in bed and say: 'What the heck was that?'

Even after 30 years still do a lot of saying: 'What the heck was that?' You imagine all sorts - a bomb exploding, the roof coming in, the world ending.
A MULTI-CHANNEL DEPLOYMENT MODEL

CHANNEL DEPLOYMENT

- RETAIL CHANNEL
- ONLINE
- GLOBAL RETAIL PHARMACY

SPECIALISTS

- GP'S
- DENTISTS
- SLEEP CLINICS
- ENT SURGEONS
- HOSPITALS
RAPIDLY EXPANDING GLOBAL DISTRIBUTION

NOW TARGETING – 15,000+ retail stores globally by end CY17
- 2000 Pharmacies in Australia and New Zealand
- 1200 Pharmacies in UK
- 1200 Pharmacies in Canada
- 2500 Pharmacies in Europe
- 15,000 Pharmacies in USA

US Launch May
1000 pharmacies

Appoint American
Sports Distributor

Appoint Canadian
Distributor

Launched Australia

2015 2016 2017
INNOVATION PIPELINE
END TO END SLEEP CATEGORY SOLUTIONS

SNORING

NASAL CONGESTION

MILD/MODERATE SLEEP APNEA

SEVERE SLEEP APNEA

ON MARKET

MUTE ‘CLEAR’
Aroma enhanced (menthol, eucalypt, sleep & relaxation blends)

RNO INPEAP
Clinical trials (Reporting first half 2016)

RNO ASPIRE
Combination Adjunct Therapy
RNO + CPAP Mask
RNO + Mandibular Splint

© RHINOMED LTD 2015
WWW.RHINOMED.GLOBAL
NEXT GENERATION NASAL DECONGESTANT
US$8 Billion Decongestion Market

MUTE
- In market
- Resolves snoring
- Improves sleep quality
- Adjunct to existing sleep therapies

MUTE ‘CLEAR’
- Next generation multi formulation platform
- Overnight nasal decongestant
- Class 1 product – regulatory process commencing
- Design being finalised and production scoping underway
- TARGET RELEASE – DECEMBER 2016
**SLEEP APNEA – US$32 BILLION OPPORTUNITY**

- Existing Industry Revenues - US$19 BILLION+
- Vast majority of patients remain undiagnosed - significant growth opportunities
- According to McKinsey & Co analysis (Harvard Medical School, 2010) the annual total costs of OSA is $165 billion

<table>
<thead>
<tr>
<th>WISCONSIN SLEEP COHORT STUDY</th>
<th>CLASS</th>
<th>%</th>
<th>US POP PREVALENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEMALE</td>
<td>MILD</td>
<td>9%</td>
<td>14 MILLION</td>
</tr>
<tr>
<td></td>
<td>SEVERE</td>
<td>4%</td>
<td>6.2 MILLION</td>
</tr>
<tr>
<td>MALE</td>
<td>MILD</td>
<td>24%</td>
<td>36.8 MILLION</td>
</tr>
<tr>
<td></td>
<td>SEVERE</td>
<td>9%</td>
<td>13.8 MILLION</td>
</tr>
</tbody>
</table>

70% of all OSA patients are MILD/MODERATE OSA
WITH A BILLION DOLLAR PROBLEM

• 80% of those with sleep apnea remain undiagnosed
• CPAP compliance rates are poor - less than 38%
• CPAP and MDS treatment is expensive $2000+
• Few clinically proven alternative treatments
• All existing treatments are highly invasive
• Existing therapies struggle to attract and retain patients
MUTE – AN ADJUNCT TO EXISTING OSA THERAPIES

- Proof of compliance is increasingly required by insurers before reimbursement
- RHINOMED nasal stent lowers nasal resistance
- Being increasingly recommended by Sleep Specialists, Sleep Technicians and ENT’s as an adjunct therapy to Mandibular Advancement Devices and Low AHI Patients to resolve compliance issues
- Working closely with sleep specialists to begin scoping trial
INPEAP – A NEW FRONT LINE SLEEP APNEA THERAPY

Intranasal Positive Expiratory Airway Pressure (INPEAP)

• Patented INPEAP technology
• Targeting 70% of OSA patients with moderate OSA (AHI 14-29)
• Low invasive
• Well tolerated
• Nasal stenting coupled with nasally delivered EPAP
• Trial underway at Monash Lung and Sleep Dept. Monash Health
Drug Delivery – Proof of Concept

- 37 million Americans suffer from migraine
- <25% are satisfied with their existing therapy
- US$1.6 billion – Worldwide sales of Imitrex
- Efficacy and safety established
- 7,026,000 sumatripan prescriptions
- Will seek to partner this program
SUMMARY

• Compelling technology in a growing global market
• Business is rapidly expanding revenue base through global distribution footprint
• Key focus is expansion in:
  • USA and Canada
  • UK
  • Aust/NZ base
• Near Term new flow – more distribution agreements, Sleep Apnea Trial results expected
• Cash on hand ~ AU$4.0 million
• Compelling investment comparator – Breathe Right Strips – purchased by GSK- US$566m in 2007
MICHAEL JOHNSON, CEO

e. mjohson@rhinomed.global
t. +61 3 8416 0900
w. rhinomed.global